Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00049829 |
HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.
Condition | Intervention | Phase |
---|---|---|
Osteoporosis |
Drug: Zoledronic Acid |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | HORIZON-PFT: Pivotal Fracture Trial |
Ages Eligible for Study: | 65 Years to 89 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Study ID Numbers: | CZOL446H2301 |
Study First Received: | November 14, 2002 |
Last Updated: | October 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00049829 |
Health Authority: | United States: Food and Drug Administration |
Bisphosphonate,BMD,Height loss, Hip protectors,HRT, Osteoporosis |
Diphosphonates Zoledronic acid Musculoskeletal Diseases Fractures, Bone |
Osteoporosis Bone Diseases, Metabolic Bone Diseases |
Physiological Effects of Drugs Bone Density Conservation Agents Pharmacologic Actions |